Orion Oyj (ORINF) Stock Price, News & Analysis

Company Overview

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Key Stats

• Today's Range: $48.65 to $48.65
• 50-Day Range: $47.79 to $48.65
• 52-Week Range: $48.65 to $48.65
• Volume: N/A
• Average Volume: 1,080 shs
• Market Capitalization: N/A
• P/E Ratio: 30.28
• Dividend Yield: 2.57%
• Price Target: N/A
• Consensus Rating: N/A

Orion Oyj Stock Analysis - MarketRank™

Orion Oyj scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Orion Oyj.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Orion Oyj is 30.28, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.32.

Price to Earnings Ratio vs. Sector

The P/E ratio of Orion Oyj is 30.28, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.24.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Orion Oyj has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Orion Oyj has recently decreased by 21.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Orion Oyj is a leading dividend payer. It pays a dividend yield of 5.22%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Orion Oyj does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Orion Oyj is 77.80%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Orion Oyj has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Orion Oyj has recently decreased by 21.28%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Orion Oyj this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Orion Oyj insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 18.76% of the stock of Orion Oyj is held by institutions.

ORINF Stock Analysis - Frequently Asked Questions

How have ORINF shares performed this year?

Orion Oyj's stock was trading at $48.65 at the beginning of 2025. Since then, ORINF shares have increased by 0.0% and is now trading at $48.65.

How do I buy shares of Orion Oyj?

Shares of ORINF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/14/2025
• Next Earnings (Estimated): 7/18/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:ORINF
• CIK: N/A
• Web: www.orion.fi
• Phone: 358104261
• Fax: N/A
• Employees: 3,819
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 30.28
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A